Leerink analyst Andrew Berens lowered the firm’s price target on Immunome (IMNM) to $33 from $37 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
- Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
- Immunome reports Q1 EPS (48c), consensus (54c)
- Immunome announces submission of NDA for varegacestat in desmoid tumors
- Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s